On Wednesday, Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), added 15.71% and closed at $4.05 in the last trading session. The last trading range of the stock ranges between $3.53 and $4.13. The company’s Market capitalization is $123.51 million with the total Outstanding Shares of 35.29 million. Aurinia Pharmaceuticals Inc. (AUPH) (AUP.TO) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, recently declared that in addition to voclosporin (23.7 mg BID) achieving its primary endpoint of Complete Remission (CR) at 24 weeks, both doses of voclosporin when added to the current standard of care of Mycophenolate Mofetil (MMF) and a forced oral corticosteroid taper have met all 24-week pre-specified secondary endpoints vs the control group. These pre-specified endpoints include: Partial Remission (PR), which is measured by a ≥50% reduction in UPCR with no concomitant use of rescue medication; time to CR and PR; reduction in Systemic Lupus Erythematosus Disease Activity Index or SLEDAI score; and reduction in UPCR over the 24-week treatment period. The AURA-LV study remains ongoing to its 48-week endpoint upon which similar and additional secondary analysis will be analysed and presented early next year.
“We are thrilled by the results of the AURA study and voclosporin’s potential to shift the treatment paradigm for active lupus nephritis,” said Charles Rowland, CEO of Aurinia. “The ability to get more patients into remission and in a shorter period time than the current standard of care can have a noteworthyimpact on the long-term outcomes for these patients.”
Endo International plc – Ordinary Shares (NASDAQ:ENDP), jumped 5.05% and closed at $21.42 in the last trading session. The last trading range of the stock ranges between $20.46 and $21.66. The company’s Market capitalization is $4.54 Billion with the total Outstanding Shares of 222.77 million. Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Branded Pharmaceuticals segment offers chronic pain administration products, such as BELBUCA, OPANA ER, and Percocet; Lidoderm for opioid analgesics; and Voltaren gel for osteoarthritis pain, in addition to XIAFLEX for treating Peyronies and Dupuytrens contracture diseases. This segment also provides Supprelin LA for central precocious puberty treatment; testosterone replacement therapies, such as Aveed and TESTOPEL, in addition to Fortesta and Testim gels; Frova and Sumavel DosePro for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; and Vantas for the palliative treatment of prostate cancer. The companys U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain administration, urology, central nervous system disorders, immunosuppression, oncology, womens health, and cardiovascular disease markets. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, counting attention deficit hyperactivity disorder, pain, womens health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, in addition to for government healthcare programs. The company also provides Monarc subfascial hammock to treat female stress urinary incontinence; and Elevate transvaginal pelvic floor repair system for the treatment of pelvic organ prolapse.
PNC Financial Services Group Inc (NYSE:PNC), gained 1.13% and closed at $91.52 in the last trading session. The last trading range of the stock ranges between $90.34 and $91.94. During the 52-week trading session the minimum price at which share price traded, registered at $77.40 and reached to max level of $97.50. The PNC Financial Services Group, Inc. operates as a diversified financial services company in the United States and internationally. The companys Retail Banking segment offers deposit, lending, brokerage, investment administration, and cash administration services to consumer and small business customers through branch network, ATMs, call centers, online banking, and mobile channels. As of March 31, 2016, this segment operated a network of 2,613 branches and 8,940 ATMs. Its Corporate & Institutional Banking segment provides secured and unsecured loans, letters of credit, equipment leases, cash and investment administration, receivables administration, disbursement and funds transfer, information reporting, trade services, foreign exchange, derivatives, securities, loan syndications, mergers and acquisitions advisory, equity capital markets advisory, and related services for corporations, government, and not-for-profit entities. This segment also offers commercial loan servicing, and real estate advisory and technology solutions for the commercial real estate finance industry. The companys Asset Administration Group segment provides investment and retirement planning, customized investment administration, private banking, tailored credit solutions, and trust administration and administration for individuals and their families; multi-generational family planning products; and mutual funds and institutional asset administration services. Its Residential Mortgage Banking segment offers first lien residential mortgage loans. The companys BlackRock segment provides investment and risk administration services to institutional and retail clients. Its Non-Planned Assets Portfolio segment offers consumer residential mortgage, brokered home equity loans, and lines of credit, in addition to commercial real estate loans and leases.